Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: No evidence of increased efficacy
Authors: Mainwaring, P.N., Nicolson, M.C., Hickish, T., Penson, R., Joel, S., Slevin, M. and Smith, I.E.
Journal: British Journal of Cancer
Volume: 76
Issue: 12
Pages: 1636-1639
ISSN: 0007-0920
DOI: 10.1038/bjc.1997.609
Abstract:Two open, phase II studies were performed to evaluate the activity and toxicity of infusional topotecan in patients with advanced non-small-cell lung carcinoma (NSCLC) and advanced breast cancer who had not received previous chemotherapy for metastatic disease. Twenty-five patients with an ECOG performance score < 2 were treated with infusional topotecan administered as a daily, continuous intravenous infusion starting at 0.6 mg m-2 day-1 (NSCLC) and 0.5 mg m-2 day-1 (breast cancer) for 21 days every 4 weeks. Three patients achieved a partial response as defined by WHO criteria: one with NSCLC (8%; 95% CI 0-39%) and two with advanced breast cancer (15%; 95% CI 2-45%). The major toxicities were neutropenia and thrombocytopenia, with one episode of neutropenic sepsis. These data suggest that topotecan delivered as a continuous intravenous infusion over 21 days as single-agent therapy does not appear to offer a clinical advantage over conventional 5-day schedules against advanced NSCLC and advanced breast cancer.
Source: Scopus
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
Authors: Mainwaring, P.N., Nicolson, M.C., Hickish, T., Penson, R., Joel, S., Slevin, M. and Smith, I.E.
Journal: Br J Cancer
Volume: 76
Issue: 12
Pages: 1636-1639
ISSN: 0007-0920
DOI: 10.1038/bjc.1997.609
Abstract:Two open, phase II studies were performed to evaluate the activity and toxicity of infusional topotecan in patients with advanced non-small-cell lung carcinoma (NSCLC) and advanced breast cancer who had not received previous chemotherapy for metastatic disease. Twenty-five patients with an ECOG performance score < 2 were treated with infusional topotecan administered as a daily, continuous intravenous infusion starting at 0.6 mg m(-2) day(-1) (NSCLC) and 0.5 mg m(-2) day(-1) (breast cancer) for 21 days every 4 weeks. Three patients achieved a partial response as defined by WHO criteria: one with NSCLC (8%; 95% CI 0-39%) and two with advanced breast cancer (15%; 95% CI 2-45%). The major toxicities were neutropenia and thrombocytopenia, with one episode of neutropenic sepsis. These data suggest that topotecan delivered as a continuous intravenous infusion over 21 days as single-agent therapy does not appear to offer a clinical advantage over conventional 5-day schedules against advanced NSCLC and advanced breast cancer.
Source: PubMed
Preferred by: Tamas Hickish
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy
Authors: Mainwaring, P.N., Nicolson, M.C., Hickish, T., Penson, R., Joel, S., Slevin, M. and Smith, I.E.
Journal: BRITISH JOURNAL OF CANCER
Volume: 76
Issue: 12
Pages: 1636-1639
ISSN: 0007-0920
DOI: 10.1038/bjc.1997.609
Source: Web of Science (Lite)
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
Authors: Mainwaring, P.N., Nicolson, M.C., Hickish, T., Penson, R., Joel, S., Slevin, M. and Smith, I.E.
Journal: British journal of cancer
Volume: 76
Issue: 12
Pages: 1636-1639
eISSN: 1532-1827
ISSN: 0007-0920
DOI: 10.1038/bjc.1997.609
Abstract:Two open, phase II studies were performed to evaluate the activity and toxicity of infusional topotecan in patients with advanced non-small-cell lung carcinoma (NSCLC) and advanced breast cancer who had not received previous chemotherapy for metastatic disease. Twenty-five patients with an ECOG performance score < 2 were treated with infusional topotecan administered as a daily, continuous intravenous infusion starting at 0.6 mg m(-2) day(-1) (NSCLC) and 0.5 mg m(-2) day(-1) (breast cancer) for 21 days every 4 weeks. Three patients achieved a partial response as defined by WHO criteria: one with NSCLC (8%; 95% CI 0-39%) and two with advanced breast cancer (15%; 95% CI 2-45%). The major toxicities were neutropenia and thrombocytopenia, with one episode of neutropenic sepsis. These data suggest that topotecan delivered as a continuous intravenous infusion over 21 days as single-agent therapy does not appear to offer a clinical advantage over conventional 5-day schedules against advanced NSCLC and advanced breast cancer.
Source: Europe PubMed Central